Clinical trial

The Microbiome in (Non-) Obese Pregnancy and Pregnancy Outcomes

Recruiting now · Not applicable · 1 countries · Registry ID NCT05754645

Recruiting nowNot applicableObservational

What this study is about

This research aims to elucidate an underlying mechanism of maternal obesity induced pregnancy and longterm health complications for mothers and their offspring.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 45 Years
SexFemale
Healthy volunteersAccepted
ConditionObesity, Maternal, Pregnancy Complications, Gut Microbiota

Full registry criteria

Inclusion Criteria: * Participation in Predict study * Preconceptional women who wish to become pregnant or pregnancy \<13 weeks of gestational age. * BMI \> 30 kg/m2 or 18-25 kg/m2 * Understanding of Dutch in speaking and reading * Willingness to give written informed consent Exclusion Criteria: * Age \< 18 years and \> 45 years. * ≥13 weeks of gestational age * Multiple pregnancy * Smoking * Gastro-intestinal diseases, heart diseases, liver, pancreas and kidney diseases. * Use of antibiotics \< 2 weeks before sampling * Pre-existent diabetes mellitus

Treatments and study arms

Blood withdrawal

Other

venous punction with blood withdrawal Vaginal and rectal swab, done by patient itself

Primary outcomes

Gut and vaginal microbiotaPreconceptional (up to 1 year before pregnancy)

Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16S ribosomal ribonucleic acid (16SrRNA) gene amplification sequencing (V6-V8). Sequences will be assigned to operational taxonomic units (OTUs).

Gut and vaginal microbiotaFirst trimester (between 7-12 weeks gestational age)

Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.

Gut and vaginal microbiotaSecond trimester (between 22-25 weeks gestational age)

Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.

Gut and vaginal microbiotaThird trimester (between 30-32 weeks gestational age)

Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.

Gut and vaginal microbiotaAntepartum (during delivery)

Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.

Gut and vaginal microbiotaPostpartum (6-8 weeks post delivery)

Composition of gut and vaginal microbiota derived by swab sampling, bacteriome profiles will be assessed by 16SrRNA gene amplification sequencing (V6-V8). Sequences will be assigned to OTUs.

Study locations

1 locations were listed when this page was built. The first 40 are shown.

Erasmus MC🇳🇱 Rotterdam, South Holland, Netherlands
Nicole Schenkelaars, MDContact
Ann M. VanrolleghemContact
Sam Schoenmakers, MD, PhDPrincipal Investigator